WO2016086556A1 - 一种葡萄糖酸锌组合物咀嚼片及其制备方法 - Google Patents

一种葡萄糖酸锌组合物咀嚼片及其制备方法 Download PDF

Info

Publication number
WO2016086556A1
WO2016086556A1 PCT/CN2015/075384 CN2015075384W WO2016086556A1 WO 2016086556 A1 WO2016086556 A1 WO 2016086556A1 CN 2015075384 W CN2015075384 W CN 2015075384W WO 2016086556 A1 WO2016086556 A1 WO 2016086556A1
Authority
WO
WIPO (PCT)
Prior art keywords
zinc gluconate
liquid
chewable tablet
solution
keep
Prior art date
Application number
PCT/CN2015/075384
Other languages
English (en)
French (fr)
Inventor
石金友
汪金灿
郝结兵
吴函峰
汪志琼
Original Assignee
海南卫康制药(潜山)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 海南卫康制药(潜山)有限公司 filed Critical 海南卫康制药(潜山)有限公司
Publication of WO2016086556A1 publication Critical patent/WO2016086556A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Definitions

  • the invention relates to the technical field of medicine and medicine production, in particular to a chewable tablet of zinc gluconate composition and a preparation method thereof.
  • the tablet is stable in quality and convenient to take, and is the most basic and most commonly used form of preparation.
  • ordinary tablets are often difficult to take, and long-term medication may even cause psychological refusal, and chewable tablets can make up for this deficiency.
  • Chewable tablets are a type of tablets that can be swallowed after being chewed in the oral cavity.
  • the size is generally the same as that of ordinary tablets, and shaped tablets of different shapes can be made as needed.
  • the tablets are easily swallowed after being chewed, and the surface area of the tablets is increased to promote the dissolution and absorption of the drug in the body.
  • making chewable tablets can accelerate their disintegration and improve drug efficacy.
  • Chewable tablets are convenient to take, even in the absence of water, can be used on time, especially for children, the elderly, patients with dysphagia or poor gastrointestinal function, can reduce the burden of drugs on the gastrointestinal tract. Therefore, chewing tablet applications are becoming more widespread.
  • Zinc gluconate is used to treat malnutrition caused by zinc deficiency, anorexia, pica, oral ulcers, hemorrhoids, and growth retardation in children.
  • the pharmaceutical preparations of zinc gluconate that have been marketed include ordinary tablets, syrups, ointments, granules, capsules, chewable tablets, oral solutions, sprays, etc., among which the types and amounts of zinc gluconate chewable tablets are generally used. Fillers, lubricants, disintegrants, binders, flavors, etc., and at least 4 excipients are used. More and more studies have shown that the side effects of the excipient itself, the incompatibility of the excipients with the main drug, the impurities in the excipients, etc. all have an impact on the safety of the drug.
  • Starch is a polymer of glucose molecules, which is a basic excipient for oral solid preparations.
  • a binder a diluent and a disintegrating agent in the chewable tablet, and the starch is extracted from natural substances such as corn and cassava, it is safe, reliable and cheap, but the use of starch alone as an auxiliary material for the production of chewable tablets has not been reported.
  • the technical problem to be solved by the present invention is to overcome the defects of the prior art, and further to provide a zinc gluconate composition chewable tablet and a preparation method thereof, which have less auxiliary materials, good stability and high bioavailability.
  • a zinc gluconate composition chewable tablet comprising zinc gluconate, starch and sucrose, the tablet overcomes the disadvantages of the above ordinary chewable tablet, and reduces the type and amount of excipients in the zinc gluconate chewable tablet, and the pharmaceutical preparation has excellent performance. High bioavailability, good stability, high patient acceptance, no gritty, and important clinical application value.
  • a zinc gluconate composition chewable tablet prepared from the following materials:
  • a preparation method of a zinc gluconate composition chewable tablet comprising the following steps:
  • step C mixing the liquid obtained in step A with the solution obtained in step B, stirring well for 30 minutes, and then reducing the liquid to normal temperature to obtain a gelatinized corn-sucrose system liquid;
  • step E sampling the liquid obtained in step D to measure the content of zinc gluconate, using sodium hydroxide or hydrochloric acid to control the pH value between 5.5 and 7.5;
  • the liquid is dispensed into the medicinal dish according to the loading amount, and each medicinal dish is filled with about 1.0 ml, and then the medicinal dish is covered with the unfilled state of the medicinal dish cover.
  • the medicinal dish is a cylindrical drug-loading package made of plastic or other materials;
  • step A sodium hydroxide or hydrochloric acid
  • the stirring time in the step C is preferably 30 minutes
  • the pH value in step D is preferably controlled at 6.5.
  • step F the temperature is gradually increased to 0 ° C for 3 hours, and then gradually heated to 30 ° C for 5 hours; the starch is selected from corn starch.
  • the preparation method of the chewable tablet of the zinc gluconate composition of the invention adopts a unique process step, and special treatment of the common corn starch can improve the adhesion and disintegration of the starch in the chewable tablet and improve the chewing.
  • the amount of sucrose in the chewable tablet of the zinc gluconate composition is 8.5% (W/V), which is the hardness enhancer of the tablet, and plays a flavoring effect.
  • the chewing tablets of the zinc gluconate composition only need starch and sucrose. Excipients, reduce the types of excipients needed; because the freeze-drying process uses two two-liter process, two cooling and two warming can make the chewable sheet more formable, improve product stability and dissolution, and improve the product. Quality and bioavailability. Therefore, the preparation method of the zinc gluconate composition chewable tablet provided by the invention has the characteristics of convenient operation, simple prescription, unique process, high product stability and high safety.
  • Figure 1 is a graph comparing the dissolution of zinc gluconate in the experiment.
  • the zinc gluconate content is exemplified by 35 mg/tablet.
  • A weigh 100g of corn starch, add 900ml of purified water to stir, adjust the pH of the solution to 6.5 with pH adjuster, then heat to 72 ° C, hold for 120 minutes, make about 10% (W / V) Paste corn starch solution.
  • the drug solution obtained in the step A is mixed with the solution obtained in the step B, stirred well for 30 minutes, and then the drug solution is lowered to normal temperature to obtain a gelatinized corn-sucrose system drug solution.
  • step E Sampling the liquid obtained in step D to measure the zinc gluconate content, and controlling the pH to 6.5 with sodium hydroxide or hydrochloric acid.
  • the liquid is dispensed into the medicinal dish according to the loading amount, and each medicinal dish is filled with about 1.0 ml, and then the medicinal dish is covered with the unfilled state of the medicinal dish cover.
  • the medicinal dish is a cylindrical drug-loading package made of plastic or other materials.
  • A weigh 150g of corn starch, add 900ml of purified water to stir, adjust the pH of the solution to 6.5 with pH adjuster, then heat to 72 ° C, hold for 120 minutes, make about 5 to 15% (W / V a gelatinized corn starch solution.
  • the drug solution obtained in the step A is mixed with the solution obtained in the step B, stirred well for 30 minutes, and then the drug solution is lowered to normal temperature to obtain a gelatinized corn-sucrose system drug solution.
  • step E Sampling the liquid obtained in step D to measure the zinc gluconate content, and controlling the pH to 6.5 with sodium hydroxide or hydrochloric acid.
  • the liquid is dispensed into the medicinal dish according to the loading amount, and each medicinal dish is filled with about 1.0 ml, and then the medicinal dish is covered with the unfilled state of the medicinal dish cover.
  • the medicinal dish is a cylindrical drug-loading package made of plastic or other materials.
  • the zinc gluconate composition chewable tablet prepared according to the above examples and the commercially available zinc gluconate chewable tablet (commercially available) were tested for friability and hardness according to the Chinese Pharmacopoeia 2010 edition two appendix X G inspection method. The results are as follows:
  • Example 1 Hardness / N Brittleness Taste Example 1 63 ⁇ 1% No graininess, crispy Example 2 68 ⁇ 1% No graininess, crispy Ordinary film (commercially available) 74 ⁇ 1% Has a grainy feel, harder
  • the experimental data showed that the zinc gluconate composition chewable tablets had no significant difference in friability and hardness compared with the commercially available zinc gluconate chewable tablets, which met the requirements of the Chinese Pharmacopoeia 2010 edition for chewing tablets, and the taste was very large. Improve to make it more in line with the needs of patients.
  • Zinc gluconate composition chewable tablets (No. 1 to No. 3 are the first embodiment, No. 4 to No. 6 are the second embodiment)
  • Zinc gluconate chewable tablets (commercially available)
  • the dissolution profile was plotted against the average of the dissolution values, as shown in Figure 1.
  • the dissolution rate of the zinc gluconate composition chewable tablet of the present invention at 20 min was compared with the chewable tablet of the zinc gluconate composition of the present invention and the commercially available reference preparation according to the above method (86.7%).
  • the dissolution rate (85.8%) was comparable to that of the zinc gluconate chewable tablet (commercially available) at 30 min, and the dissolution rate (92.6%) of the zinc gluconate composition chewable tablet of the present invention at 30 min was higher than that of the zinc gluconate chewable tablet (
  • the commercially available) dissolution rate (85.8%) at 30 min is higher, indicating that the zinc gluconate composition chewable tablet of the present invention has a shorter dissolution time and a higher dissolution rate than the zinc gluconate chewable tablet (commercially available), further indicating The zinc gluconate composition chewable tablet of the present invention is superior in bioavailability to zinc gluconate chewable tablets (commercially available).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种葡萄糖酸锌咀嚼片及其制备方法，所述咀嚼片由葡萄糖酸锌、淀粉、蔗糖和纯化水制成，其制备方法包括将淀粉与蔗糖分别加水制成溶液，将二者混合，加入葡萄糖酸锌，然后将该药液放到圆柱状盛药皿中，冻干。

Description

一种葡萄糖酸锌组合物咀嚼片及其制备方法 技术领域
本发明涉及医药及医药生产技术领域，具体涉及一种葡萄糖酸锌组合物咀嚼片及其制备方法。
背景技术
片剂质量稳定、服用方便，是一种最基本、最常用的制剂形式。然而，对于儿童、老人以及吞咽困难的患者，普通片剂往往服用困难，长期服药甚至会使其产生心理上的拒药现象，咀嚼片则可弥补这种不足。咀嚼片是一类可在口腔内嚼碎后咽下的片剂，大小一般与普通片剂相同，可根据需要制成不同形状的异形片。药片经嚼碎后便于吞服，药片表面积增大，可促进药物在体内的溶解、吸收。对于难崩解的药物，制成咀嚼片可加速其崩解，提高药效。咀嚼片服用方便，即使在缺水的条件下也可以按时用药，特别适用于小儿、老人、吞咽困难或胃肠功能较差的患者，可减少药物对胃肠道的负担。因此，咀嚼片剂应用逐渐广泛起来。
葡萄糖酸锌用于治疗缺锌引起的营养不良、厌食症、异食癖、口腔溃疡、痤疮、儿童生长发育迟缓等。
已上市的葡萄糖酸锌的药物制剂有普通片剂、糖浆、软膏、颗粒、胶囊、咀嚼片、口服溶液、喷雾剂等等，其中葡萄糖酸锌咀嚼片辅料种类及数量较多，一般要用到填充剂、润滑剂、崩解剂、黏合剂、矫味剂等等，而且至少要用到4种辅料。越来越多的研究表明辅料本身的毒副作用、辅料与主药的配伍禁忌、辅料中的杂质等等都会对药品的安全性产生影响，
因此，选择合适的辅料和工艺，减少葡萄糖酸锌咀嚼片的辅料种类和用量，提高葡萄糖酸锌咀嚼片的生物利用度和稳定性，对于保证临床用药的安全性有积极意义。
淀粉是由葡萄糖分子聚合而成，它是口服固体制剂的基本辅料，常用于 咀嚼片中作黏合剂、稀释剂及崩解剂，且淀粉均从玉米、木薯等天然物质中提取，安全可靠、廉价易得，但是单独使用淀粉作为辅料用于咀嚼片的生产未见报道。
发明内容
本发明所要解决的技术问题在于克服现有技术的缺陷，进一步提出一种葡萄糖酸锌组合物咀嚼片及其制备方法，该制剂辅料少，稳定性好，生物利用度高。
本发明所要解决的技术问题采用以下技术方案来实现：
一种葡萄糖酸锌组合物咀嚼片，包含葡萄糖酸锌、淀粉、蔗糖，该片剂克服了上述普通咀嚼片的缺点，减少了葡萄糖酸锌咀嚼片中辅料种类和用量，该药物制剂性能优良，生物利用度高，稳定性良好，患者接受度高，无砂砾感，具有重要的临床应用价值。
一种葡萄糖酸锌组合物咀嚼片，由如下原料制备而成：
Figure PCTCN2015075384-appb-000001
一种葡萄糖酸锌组合物咀嚼片的制备方法，包括步骤如下：
A、称取组份量的淀粉，加入一定量的纯化水搅拌，用pH调节剂将溶液的pH值控制在4～9之间,然后加热至72℃，保温120分钟，制成5～15％(W/V)的糊化玉米淀粉溶液；
B、量取纯化水45ml，煮沸，加85g蔗糖，搅拌，溶解后，继续加热至100℃，用精制棉滤过，滤器用适量的热蒸馏水洗净，洗液与滤液合并，放冷，加适量的蒸馏水，使全量成100mL，搅匀，即得B溶液；
C、将步骤A得到的药液与步骤B得到的溶液混合，充分搅拌30分钟，后将药液降至常温得到糊化玉米-蔗糖体系药液；
D、称取葡萄糖酸锌35克，加入1L糊化玉米-蔗糖体系药液，搅拌25～35分钟；
E、对步骤D得到的药液取样测量葡萄糖酸锌含量，用氢氧化钠或盐酸将pH值控制在5.5～7.5之间；
F、药液测量葡萄糖酸锌含量后，按装量将药液分装于盛药皿中，每个盛药皿装约1.0ml，然后利用盛药皿盖未压紧状态盖住盛药皿，盛药皿为塑料或其他材料制成的圆柱状载药包装；
G、将装有药液的盛药皿放入冷冻干燥箱，降温至零下45℃，保持2小时，抽真空，然后逐渐升温至0℃，保持2小时，再降温至零下45℃，保持2小时，再逐渐升温至0℃，保持2～4小时，再逐渐升温至28～32℃干燥4～6小时，整个过程真空度保持在10帕以下；最后将装药的盛药皿盖盖紧，并装入铝箔袋进行密封得到葡萄糖酸锌组合物咀嚼片。
本发明的一种葡萄糖酸锌组合物咀嚼片的制备方法，所述步骤A中pH调节剂为氢氧化钠或盐酸，优选将溶液的pH值控制在6.5；步骤C中搅拌时间优选30分钟；步骤D中pH值优选控制在6.5，步骤F中优选再逐渐升温至0℃，保持3小时，再逐渐升温至30℃干燥5小时；所述淀粉选用玉米淀粉。
本发明的有益效果为：
本发明的一种葡萄糖酸锌组合物咀嚼片的制备方法，其采用独特的工艺步骤，对普通玉米淀粉进行特殊工艺处理，可以提高淀粉在咀嚼片剂中的粘合、崩解作用，提高咀嚼片剂的成型。且葡萄糖酸锌组合物咀嚼片中蔗糖用量为8.5％(W/V)，它是此片剂的硬度增强剂，并起到矫味作用葡萄糖酸锌组合物咀嚼片只需淀粉和蔗糖两种辅料，减少所需用辅料的种类；由于冻干工艺采用两降两升的工艺，两次降温、两次升温能够使咀嚼片成型性更好，并提高产品的稳定性和溶出度，提高产品的质量和生物利用度。因此本发明提供的一种葡萄糖酸锌组合物咀嚼片的制备方法具有操作方便，处方简单，工艺独特，产品稳定性、安全性高的特点。
附图说明
图1为实验中葡萄糖酸锌的溶出度对比曲线图。
具体实施方式
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解，下面结合具体实施例，进一步阐述本发明，但下述实施例仅仅为本发明的优选实施例，并非全部。基于实施方式中的实施例，本领域技术人员在没有做出创造性劳动的前提下所获得其它实施例，都属于本专利的保护范围。
葡萄糖酸锌含量以35mg/片为例。
实施例1
处方：1000片量
Figure PCTCN2015075384-appb-000002
A、称取100g的玉米淀粉，加入900ml的纯化水搅拌，用pH调节剂将溶液的pH值控制在6.5,然后加热至72℃，保持120分钟，制成约10％(W/V)的糊化玉米淀粉溶液。
B、量取纯化水45ml，煮沸，加85g蔗糖，搅拌，溶解后，继续加热至100℃，用精制棉滤过，滤器用适量的热蒸馏水洗净，洗液与滤液合并，放冷，加适量的蒸馏水，使全量成100mL，搅匀，即得B溶液。
C、将步骤A得到的药液与步骤B得到的溶液混合，充分搅拌30分钟，后将药液降至常温得到糊化玉米-蔗糖体系药液。
D、称取葡萄糖酸锌35g(按1000片算)，加入1L糊化玉米-蔗糖体系药液，搅拌30分钟。
E、对步骤D得到的药液取样测量葡萄糖酸锌含量，用氢氧化钠或盐酸将pH值控制在6.5。
F、药液测量葡萄糖酸锌含量后，按装量将药液分装于盛药皿中，每个盛药皿装约1.0ml，然后利用盛药皿盖未压紧状态盖住盛药皿，盛药皿为塑料或其他材料制成的圆柱状载药包装。
G、将装有药液的盛药皿放入冷冻干燥箱，降温至零下45℃，保持2小时，抽真空，然后逐渐升温至0℃，保持2小时，降温至零下45℃，保持2小时，再逐渐升温至0℃，保持3小时，再逐渐升温至30℃干燥5小时，整个过程真空度 保持在10帕以下。最后将装药的盛药皿盖盖紧，并装入铝箔袋进行密封得到一种葡萄糖酸锌组合物咀嚼片。
实施例2
处方：1000片量
Figure PCTCN2015075384-appb-000003
A、称取150g的玉米淀粉，加入900ml的纯化水搅拌，用pH调节剂将溶液的pH值控制在6.5,然后加热至72℃，保持120分钟，制成约5～15％(W/V)的糊化玉米淀粉溶液。
B、量取纯化水45ml，煮沸，加85g蔗糖，搅拌，溶解后，继续加热至100℃，用精制棉滤过，滤器用适量的热蒸馏水洗净，洗液与滤液合并，放冷，加适量的蒸馏水，使全量成100mL，搅匀，即得B溶液。
C、将步骤A得到的药液与步骤B得到的溶液混合，充分搅拌30分钟，后将药液降至常温得到糊化玉米-蔗糖体系药液。
D、称取葡萄糖酸锌35g(按1000片算)，加入1L糊化玉米-蔗糖体系药液，搅拌30分钟。
E、对步骤D得到的药液取样测量葡萄糖酸锌含量，用氢氧化钠或盐酸将pH值控制在6.5。
F、药液测量葡萄糖酸锌含量后，按装量将药液分装于盛药皿中，每个盛药皿装约1.0ml，然后利用盛药皿盖未压紧状态盖住盛药皿，盛药皿为塑料或其他材料制成的圆柱状载药包装。
G、将装有药液的盛药皿放入冷冻干燥箱，降温至零下45℃，保持2小时，抽真空，然后逐渐升温至0℃，保持2小时，降温至零下45℃，保持2小时，再逐渐升温至0℃，保持3小时，再逐渐升温至30℃干燥5小时，整个过程真空度保持在10帕以下。最后将装药的盛药皿盖盖紧，并装入铝箔袋进行密封得到一种葡萄糖酸锌组合物咀嚼片。
实验资料
将上述实施例制得的葡萄糖酸锌组合物咀嚼片进行如下质量研究试验：
1、硬度、脆碎度、口感对比试验
根据上述实施例制备的葡萄糖酸锌组合物咀嚼片与市售葡萄糖酸锌咀嚼片(市售)按《中国药典》2010年版二部附录X G检查法检测脆碎度和硬度，进行了对比，结果见下表：
样品 硬度/N 脆碎度 口感
实施例1 63 <1％ 无沙粒感，松脆
实施例2 68 <1％ 无沙粒感，松脆
普通片(市售) 74 <1％ 有沙粒感，较硬
实验数据表明，葡萄糖酸锌组合物咀嚼片较市售葡萄糖酸锌咀嚼片在脆碎度和硬度上无显著差异，符合《中国药典》2010年版对咀嚼片剂的要求，且口感上有很大改善，使之更符合患者的需求。
2、溶出度对比试验
分别取葡萄糖酸锌咀嚼片(市售)和葡萄糖酸锌组合物咀嚼片(1号至3号为实施例1片，4号至6号为实施例2片)各6片，分别按照溶出度测定法(《中国药典》2010年版二部附录X C第一法)，，以水1000ml为溶出介质，转速为每分钟100转，依法操作，分别在5分钟、10分钟、15分钟、20分钟、25分钟、30分钟时，取溶液适量，滤过，精密量取续滤液10ml，置100ml量瓶中，用水稀释至刻度，摇匀，作为供试品溶液；另取葡萄糖酸锌对照品约14mg,精密称定，加水溶解并稀释至100ml,摇匀，精密量取lml、2ml、3ml、4ml、5ml，置100ml量瓶中，用水稀释至刻度，摇匀，作为对照品溶液。取对照品溶液与供试品溶液，照原子吸收分光光度法(附录ff D第一法)，在213.9nm的波长处测定。计算每片的溶出量。考察溶出曲线，结果如下所示。
葡萄糖酸锌组合物咀嚼片(1号至3号为实施例1片，4号至6号为实施例2片)
Figure PCTCN2015075384-appb-000004
Figure PCTCN2015075384-appb-000005
葡萄糖酸锌咀嚼片(市售)
Figure PCTCN2015075384-appb-000006
分别用溶出度平均值对时间作溶出度曲线，如图1。
按上述方法对本发明的葡萄糖酸锌组合物咀嚼片和市售参比制剂的葡萄糖酸锌组合物咀嚼片对比测定，本发明的葡萄糖酸锌组合物咀嚼片在20min时的溶出度(86.7％)与葡萄糖酸锌咀嚼片(市售)在30min时的溶出度(85.8％)相当，且本发明的葡萄糖酸锌组合物咀嚼片在30min时的溶出度(92.6％)较葡萄糖酸锌咀嚼片(市售)在30min时的溶出度(85.8％)更高，表明本发明的葡萄糖酸锌组合物咀嚼片较葡萄糖酸锌咀嚼片(市售)溶出时间更短，溶出度更高，更进一步表明本发明的葡萄糖酸锌组合物咀嚼片生物利用度要优于葡萄糖酸锌咀嚼片(市售)。
2、稳定性研究
样品来源：自制
样品批号：20131001(实施例1)、20131002(实施例2)
考察项目：性状、含量、有关物质、硬度、溶出度
考察方法：依据《中国药典》2010年版二部附录XIX C原料药与药物制剂稳定性试验指导原则，对本品的加速稳定性(1月、2月、3月、6月)和长期稳定性(3月、6月、9月、12月)进行了考察，试验结果如下表：
Figure PCTCN2015075384-appb-000007
Figure PCTCN2015075384-appb-000008
从上表可以看出，本发明的葡萄糖酸锌组合物咀嚼片各项指标在加速6个月内，长期12个月内均未发生显著变化，表明本品稳定性良好。
以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的仅为本发明的优选例，并不用来限制本发明，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。

Claims (2)

  1. 一种葡萄糖酸锌组合物咀嚼片，其特征在于，由如下原料制备而成：
    Figure PCTCN2015075384-appb-100001
  2. 一种权利要求1所述的葡萄糖酸锌组合物咀嚼片的制备方法，其特征在于，包括步骤如下：
    A、称取组份量的淀粉，加入一定量的纯化水搅拌，用pH调节剂将溶液的pH值控制在4～9之间,然后加热至72℃，保温120分钟，制成5～15％(W/V)的糊化玉米淀粉溶液；
    B、量取纯化水45ml，煮沸，加85g蔗糖，搅拌，溶解后，继续加热至100℃，用精制棉滤过，滤器用适量的热蒸馏水洗净，洗液与滤液合并，放冷，加适量的蒸馏水，使全量成100ml，搅匀，即得B溶液；
    C、将步骤A得到的药液与步骤B得到的溶液混合，充分搅拌30分钟，后将药液降至常温得到糊化玉米-蔗糖体系药液；
    D、称取葡萄糖酸锌35克，加入1L糊化玉米-蔗糖体系药液，搅拌25～35分钟；
    E、对步骤D得到的药液取样测量葡萄糖酸锌含量，用氢氧化钠或盐酸将pH值控制在5.5～7.5之间；
    F、药液测量葡萄糖酸锌含量后，按装量将药液分装于盛药皿中，每个盛药皿装约1.0ml，然后利用盛药皿盖未压紧状态盖住盛药皿，盛药皿为塑料或其他材料制成的圆柱状载药包装；
    G、将装有药液的盛药皿放入冷冻干燥箱，降温至零下45℃，保持2小时，抽真空，然后逐渐升温至0℃，保持2小时，再降温至零下45℃，保持2小时，再逐渐升温至0℃，保持2～4小时，再逐渐升温至28～32℃干燥4～6小时，整个过程真空度保持在10帕以下；最后将装药的盛药皿盖盖紧，并装入铝箔袋进行密封得到葡萄糖酸锌组合物咀嚼片。
PCT/CN2015/075384 2014-12-05 2015-03-30 一种葡萄糖酸锌组合物咀嚼片及其制备方法 WO2016086556A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410735501.4 2014-12-05
CN201410735501.4A CN104490814A (zh) 2014-12-05 2014-12-05 一种葡萄糖酸锌组合物咀嚼片及其制备方法

Publications (1)

Publication Number Publication Date
WO2016086556A1 true WO2016086556A1 (zh) 2016-06-09

Family

ID=52932332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/075384 WO2016086556A1 (zh) 2014-12-05 2015-03-30 一种葡萄糖酸锌组合物咀嚼片及其制备方法

Country Status (2)

Country Link
CN (1) CN104490814A (zh)
WO (1) WO2016086556A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112315923A (zh) * 2020-10-12 2021-02-05 安徽金太阳生化药业有限公司 一种磷酸氢钙咀嚼片的生产工艺

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107485025A (zh) * 2017-08-31 2017-12-19 广州富诺营养科技有限公司 一种富锌酵母咀嚼片及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286629A (zh) * 1997-12-29 2001-03-07 宝洁公司 片剂组合物
CN102258193A (zh) * 2011-07-19 2011-11-30 江西省农业科学院 芦笋咀嚼片的生产方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102266299B (zh) * 2011-04-06 2013-02-20 广东如来医药进出口有限公司 葡萄糖酸锌化合物的组合物咀嚼片剂及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286629A (zh) * 1997-12-29 2001-03-07 宝洁公司 片剂组合物
CN102258193A (zh) * 2011-07-19 2011-11-30 江西省农业科学院 芦笋咀嚼片的生产方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112315923A (zh) * 2020-10-12 2021-02-05 安徽金太阳生化药业有限公司 一种磷酸氢钙咀嚼片的生产工艺
CN112315923B (zh) * 2020-10-12 2022-09-06 安徽金太阳生化药业有限公司 一种磷酸氢钙咀嚼片的生产工艺

Also Published As

Publication number Publication date
CN104490814A (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
Lee et al. Orally disintegrating films focusing on formulation, manufacturing process, and characterization
Mahboob et al. Oral films: A comprehensive review
CN106420643B (zh) 一种含维生素c钠的咀嚼片及其制备方法
CN107735092A (zh) 可用于治疗急性疼痛的美洛昔康‑环糊精包合物及制备方法
TWI820673B (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途
WO2016086556A1 (zh) 一种葡萄糖酸锌组合物咀嚼片及其制备方法
WO2016086557A1 (zh) 一种维d钙组合物咀嚼片及其制备方法
EP3610858A1 (en) Smectite suspension liquid composition and method for preparing same
CN104490924A (zh) 一种硫糖铝组合物咀嚼片及其制备方法
WO2016086555A1 (zh) 一种乳酸钙组合物咀嚼片及其制备方法
Vidyadhara et al. Formulation and evaluation of amoxicillin trihydrate lozenges
CN104434972A (zh) 一种磷酸氢钙组合物咀嚼片及其制备方法
CN104490811A (zh) 一种阿司匹林组合物咀嚼片及其制备方法
CN104490804A (zh) 一种西咪替丁组合物咀嚼片及其制备方法
CN104490815A (zh) 一种枸橼酸铋钾组合物咀嚼片及其制备方法
CN102940610A (zh) 维生素b6组合物冻干口腔崩解片及其制备方法
CN104490816A (zh) 一种富马酸亚铁组合物咀嚼片及其制备方法
CN104490805A (zh) 一种辛伐他汀组合物咀嚼片及其制备方法
CN104490926A (zh) 一种碳酸钙组合物咀嚼片及其制备方法
Vijayanand et al. Development, characterization and evaluation of soft oral edible gel using gellan gum
CN108635370A (zh) 一种含有右旋糖酐铁的组合物制剂及其制备方法
TWI835118B (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途
CN104490807A (zh) 一种盐酸氨溴索组合物咀嚼片及其制备方法
CN104490813A (zh) 一种氢溴酸右美沙芬组合物咀嚼片及其制备方法
CN104490808A (zh) 一种头孢克肟组合物咀嚼片及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15865604

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15865604

Country of ref document: EP

Kind code of ref document: A1